VaxGen IPO Could Allow For Completion of AIDS Vaccine Phase III Trials
Executive Summary
VaxGen plans to meet the 2002 deadline for an AIDS vaccine NDA submission set by marketing partner Genentech with the help of an initial public offering of 3.1 mil. shares.